Procaps Group, a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents, announces its participation at CPhI Europe 2024, scheduled to take place from October 8th to 10th, 2024, in Milan, Italy. Procaps Group invites clients and prospect partners to embark on a journey towards the evolution on healthcare solutions, at booth #7B34.
With 7 manufacturing facilities across North, Central & South America, Procaps Group’s CDMO businesses - Softigel®, Sofgen Pharmaceuticals®, Softcaps®, and Funtrition® along with their team of experts, will showcase their extensive manufacturing capabilities, exclusive delivery systems and product development expertise.
By listening closely to what their customers need, Procaps is developing new cutting-edge solutions using its softgel technology platforms with the ultimate purpose of helping companies deliver innovative health solutions to patients and consumers around the world.
Procaps Group CDMO’s offerings of services and technologies will be on full display at booth #7B34 in Hall 7, including:
- Commitment to Sustainability: Procaps Group is dedicated to delivering a more sustainable future, offering solutions that support a circular approach to healthcare, especially with UnigelTM technology, a patented format that allows the development of fixed-dose combinations in one single softgel, reducing environmental waste by decreasing the number of packaging material used when manufacturing two products or more in one single format, rather than individually.
- Expanded Capacity and Capabilities: Procaps Group has been expanding its operations in North America to meet the growing demands of softgels and gummy formats. The expansion aims to increase capacity and introduce new capabilities to better serve pharmaceutical and nutraceutical partners.
- Advancements in softgels: End-to-end solutions using new methods to bring new formats that provide better adherence such as Reducedgels. This new technique is able to reduce the size of softgel products, offering several advantages that span from patient compliance, manufacturing efficiency to overall therapeutic efficacy. Other advances include a new drug delivery system also using softgels as the oral dosage form, empowered by a phospholipid matrix for enhancing bioavailability of APIs, and more.
- Specialized capabilities: Proven track record and knowledge in the development of new chemical entities, clinical trials, plus hormonal, high potency compounds and other complex oral modalities capabilities. Expertise handling successful product tech-transfers, and much more.
- Innovation in OTCs with ChewgelsTM, a solution in chewables softgels, as well as other alternative formats in chewable formats on the rise like nutritional gummies, gaining market traction and consumer preference.
This year, we are elevating your experience with an exclusive food and coffee tasting, featuring a selection of gourmet snacks and the world´s finest coffee, sourced directly from the mountains of Colombia.
Procaps Group CDMO supports customers in accelerating their drug development journey, from formulation to patient, through comprehensive services and solutions. Whether it´s a
development or a
full-scale manufacturing service, Procaps Group is equipped to
deliver for companies interested in market novel products.
To gain access to the exhibition halls, interested individuals can register online and receive a
Free Access Pass. Get the free access pass
here
Make sure you come down and visit us at
booth #7B34 or schedule a meeting with
us here
Procaps Group has been an active participant at CPhI for several years, and we eagerly anticipate meeting with customers and visitors at the event in Milan.